Cancer Family
Intestinal Neoplasm
CI-CAN-00000209Explore in graph →
Non-malignant1,893 active trials21 approved drugs383 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000209Explore in graph →
Clinical trials
9,158 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05420584 | Neoadjuvant Arterial Embolization Chemotherapy Combined PD-1 Inhibitor for Locally Advanced Rectal Cancer(NECI) | unknown | Phase 2 | 83 | The Fourth Affiliated Hospital of Zhejiang University School of MedicineOTHER | 1 | May 11, 2023 | clinicaltrials |
| NCT05845268 | Total Neoadjuvant Therapy Combined With Tislelizumab for Local Advanced of Middle and Low Rectal Cancer | unknown | Phase 2 | 102 | Beijing Friendship HospitalOTHER | 1 |
| May 6, 2023 |
| clinicaltrials |
| NCT05833672 | Neoadjuvant Immunotherapy in Locally Advanced Colon Cancers | unknown | Phase 2 | 100 | fan liOTHER | 1 | Apr 27, 2023 | clinicaltrials |
| NCT05815290 | Cadonilimab in Locally Advanced MSI-H/dMMR Colorectal Cancer | unknown | Phase 2 | 50 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Apr 18, 2023 | clinicaltrials |
| NCT05815303 | XELOX Combined With Cadonilimab Versus XELOX as Neoadjuvant Treatment for Locally Advanced, pMMR Rectal Cancer | unknown | Phase 2 | 92 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Apr 18, 2023 | clinicaltrials |
| NCT05799443 | Efficacy and Safety of SBRT Followed by Tislelizumab Plus Cetuximab and Irinotecan in Patients With Previously Treated RAS Wild-type Advanced Refractory Colorectal Cancer | unknown | Phase 2 | 23 | Fujian Cancer HospitalOTHER_GOV | 0 | Apr 5, 2023 | clinicaltrials |
| NCT05797883 | FOLFOX/FOLFIRI Containing Levofolinic Acid (Zuoyu ®) in the Treatment of Unresectable or Metastatic Colorectal Cancer | unknown | Phase 2 | 30 | China Medical University, ChinaOTHER | 1 | Apr 4, 2023 | clinicaltrials |
| NCT05278351 | Tislelizumab Plus Cetuximab and Irinotecan vs Third-line Standard-of-care in Refractory mCRC | unknown | Phase 2 | 87 | Shanghai Zhongshan HospitalOTHER | 1 | Mar 31, 2023 | clinicaltrials |
| NCT05143099 | Phase II Study of Tislelizumab Combined With Cetuximab and Irinotecan in the Treatment of Recurrent, Refractory mCRC | unknown | Phase 2 | 35 | Shanghai Zhongshan HospitalOTHER | 1 | Mar 28, 2023 | clinicaltrials |
| NCT01628211 | Second Look Laparoscopy in Colorectal Cancer(HIPEC) | unknown | Phase 2 | 140 | National Cancer Institute, NaplesOTHER | 1 | Mar 24, 2023 | clinicaltrials |
| NCT01801904 | A Phase 2 Study of Panitumumab in Patients With Cetuximab-refractory Metastatic Colorectal Cancer(PACER) | unknown | Phase 2 | 52 | National Cancer Institute, NaplesOTHER | 1 | Mar 24, 2023 | clinicaltrials |
| NCT01898104 | Preoperative Valproic Acid and Radiation Therapy for Rectal Cancer(V-shoRT-R3) | unknown | Phase 1 / Phase 2 | 152 | National Cancer Institute, NaplesOTHER | 1 | Mar 24, 2023 | clinicaltrials |
| NCT02619435 | Regorafenib Monotherapy as Second-line Treatment of Patients With RAS-mutant Advanced Colorectal Cancer(STREAM) | unknown | Phase 2 | 46 | National Cancer Institute, NaplesOTHER | 1 | Mar 24, 2023 | clinicaltrials |
| NCT03038256 | Effect of Concurrent Capecitabine-based Long-term Radiotherapy Followed by XELOX Plus TME in Patients With High Risk Rectal Cancer: a Multi-centers, Randomized Controlled, Open-Label Trial(EXPLORE) | unknown | Phase 2 | 244 | Peking University People's HospitalOTHER | 1 | Mar 22, 2023 | clinicaltrials |
| NCT04194359 | Sintilimab (IBI308) Combined With Bevacizumab + XELOX Regimen in Metastatic Colorectal Cancer | unknown | Phase 2 | 25 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Mar 17, 2023 | clinicaltrials |
| NCT05763927 | Neoadjuvant Therapy for Locally Advanced Rectal Cancer With Fruquintinib, Toripalimab and SRT | unknown | Phase 2 | 44 | West China HospitalOTHER | 1 | Mar 10, 2023 | clinicaltrials |
| NCT05429866 | Immunological Variables Associated to ICI Toxicity in Cancer Patients | unknown | Phase 2 | 441 | Jules Bordet InstituteOTHER | 1 | Mar 8, 2023 | clinicaltrials |
| NCT05755685 | Hyperthermic Intraperitoneal Treatment of rmhTNF for CRCPM: Phase II Clinical Trial | unknown | Phase 2 | 10 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Mar 6, 2023 | clinicaltrials |
| NCT05480280 | mFOLFOX6 Combined With Dalpiciclib in Patients With Metastatic Colorectal Cancer(FIND) | unknown | Phase 2 | 18 | Sixth Affiliated Hospital, Sun Yat-sen UniversityOTHER | 1 | Feb 28, 2023 | clinicaltrials |
| NCT05201612 | Pembrolizumab and Olaparib in Homologous-recombination Deficient (HRD) Advanced Colorectal Cancer (CRC).(PEMBROLA) | unknown | Phase 2 | 40 | Grupo Espanol Multidisciplinario del Cancer DigestivoOTHER | 1 | Feb 24, 2023 | clinicaltrials |
| NCT05732493 | Short-course Radiotherapy Combined With Chemotherapy and Pd-1 Inhibitor for Locally Advanced Colon Cancer(TORCH-C)(TORCH-C) | unknown | Phase 2 | 120 | Fudan UniversityOTHER | 0 | Feb 17, 2023 | clinicaltrials |
| NCT05167448 | A Study of ES104 in Patients With Metastatic Colorectal Cancer | unknown | Phase 1 / Phase 2 | 58 | Elpiscience (Suzhou) Biopharma, Ltd.INDUSTRY | 1 | Feb 15, 2023 | clinicaltrials |
| NCT05721872 | Efficacy, Tolerability and Safety of Intravenous D-VC With ATO in Patients With Advanced/Metastatic Colorectal Cancer | unknown | Phase 1 / Phase 2 | 38 | Nazarbayev UniversityOTHER | 1 | Feb 10, 2023 | clinicaltrials |
| NCT05684211 | A Study of Ametumumab in Combination With Anti-PD-1 Monoclonal Antibody and FOLFIRI in Patients With RAS Wild-type Advanced Colorectal Cancer | unknown | Phase 2 | 84 | Shanghai Celfuture Biotech Co., Ltd.INDUSTRY | 1 | Feb 1, 2023 | clinicaltrials |
| NCT05453825 | A Study of Navicixizumab Monotherapy or in Combination in Patients With Select Advanced Solid Tumors | unknown | Phase 2 | 180 | OncXerna Theraputics, Inc.INDUSTRY | 1 | Jan 31, 2023 | clinicaltrials |
| NCT05698082 | FOS Immunohistochemical Staining of Colorectal Cancer and Its Adjacent Tissues | unknown | Phase 2 / Phase 3 | 120 | xiaoliang HuangOTHER | 1 | Jan 26, 2023 | clinicaltrials |
| NCT03870607 | Prebiotics and Probiotics During Definitive Treatment With Chemotherapy-radiotherapy SCC of the Anal Canal (BISQUIT)(BISQUIT) | unknown | Phase 2 | 75 | AC Camargo Cancer CenterOTHER | 1 | Jan 17, 2023 | clinicaltrials |
| NCT05659290 | Alternating Treatment With Fruquintinib and Bevacizumab Plus Capecitabine as Maintenance Therapy After First-Line Treatment in Metastatic Colorectal Cancer | unknown | Phase 2 | 40 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Jan 6, 2023 | clinicaltrials |
| NCT03883802 | Foxy-5 as Neo-Adjuvant Therapy in Subjects With Wnt-5a Low Colon Cancer(NeoFox) | unknown | Phase 2 | 100 | WntResearch ABINDUSTRY | 1 | Dec 9, 2022 | clinicaltrials |
| NCT05640726 | The First-line Treatment of RCLM With RAS Mutation Was Local Short-course Radiotherapy (SCRT) + PD-1+ Standard Therapy | unknown | Phase 2 | 30 | Fujian Cancer HospitalOTHER_GOV | 0 | Dec 7, 2022 | clinicaltrials |
| NCT05634590 | The Efficacy and Safety of Fruquintinib Plus FOLFIRI/FOLFOX as Second-line Treatment in Patients With RAS-mutant Metastatic Colorectal Cancer | unknown | Phase 2 | 68 | Fudan UniversityOTHER | 1 | Dec 2, 2022 | clinicaltrials |
| NCT05359406 | A Combination Therapy Including Anti-PD-1 Immunotherapy in Rectal Cancer With Refractory Distal Metastasis(Miracle-2) | unknown | Phase 2 | 51 | LI XIN-XIANGOTHER | 1 | Nov 15, 2022 | clinicaltrials |
| NCT05372198 | Surufatinib With or Wothout Immunotherapy for Advanced Colorectal Cancer in Later Line | unknown | Phase 2 | 50 | Hubei Cancer HospitalOTHER | 1 | Nov 9, 2022 | clinicaltrials |
| NCT05493683 | Disitamab Vedotin Combined With Tislelizumab in Advanced HER2 Positive Colorectal Cancer | unknown | Phase 2 | 29 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Oct 21, 2022 | clinicaltrials |
| NCT05587088 | Evaluation of the Safety and Efficacy of Esperanza Extract (PA001)(PA001) | unknown | Phase 1 / Phase 2 | 82 | Hospital Universitario San IgnacioOTHER | 1 | Oct 19, 2022 | clinicaltrials |
| NCT02633098 | A Safety and Effectiveness Study of Pre-operative Artesunate in Stage II/III Colorectal Cancer(NeoART) | unknown | Phase 2 | 200 | St George's, University of LondonOTHER | 1 | Oct 12, 2022 | clinicaltrials |
| NCT05575635 | Neoadjuvant Treatment of Fruquintinib Combined With Concurrent Chemoradiotherapy for LARC | unknown | Phase 2 | 40 | Henan Provincial People's HospitalOTHER | 0 | Oct 12, 2022 | clinicaltrials |
| NCT03868228 | PIPAC for the Treatment of Colorectal Peritoneal Metastases | unknown | Phase 1 / Phase 2 | 30 | Imperial College LondonOTHER | 1 | Sep 28, 2022 | clinicaltrials |
| NCT05551247 | Envafolimab Combined With Endostatin in Recurrent or Metastatic MSS-type Colorectal Cancer | unknown | Phase 2 | 30 | First Affiliated Hospital Xi'an Jiaotong UniversityOTHER | 0 | Sep 22, 2022 | clinicaltrials |
| NCT05031975 | Temozolomide and Irinotecan in Patients With MGMT Silenced Colorectal Cancer After Adjuvant Chemotherapy(ERASE-TMZ) | unknown | Phase 2 | 35 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Sep 2, 2022 | clinicaltrials |
| NCT04398446 | Effect of Hemp-CBD on Patients With CIPN(Coala-T-CBD) | unknown | Phase 2 | 56 | Main Line HealthOTHER | 1 | Sep 1, 2022 | clinicaltrials |
| NCT05524155 | Sintilimab Combined With Regorafenib and HAIC in Patients With Colorectal Liver Metastasis | unknown | Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Sep 1, 2022 | clinicaltrials |
| NCT05279677 | FMT Combined With Immune Checkpoint Inhibitor and TKI in the Treatment of CRC Patients With Advanced Stage | unknown | Phase 2 | 30 | Chinese Academy of Medical SciencesOTHER | 1 | Aug 23, 2022 | clinicaltrials |
| NCT05314101 | TAS-102 Combined With Bevacizumab and Tislelizumab Third-line or Above in the Treatment of Liver Metastasis in Colorectal Cancer | unknown | Phase 2 | 25 | Fujian Cancer HospitalOTHER_GOV | 1 | Aug 23, 2022 | clinicaltrials |
| NCT05511051 | A Prospective Multi-centered Randomized Controlled Trial on Fruquintinib in Combination With HAIC in the Treatment of Liver Metastatic Colorectal Cancer After Failure of Second-line Systematic Therapy | unknown | Phase 2 | 102 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Aug 22, 2022 | clinicaltrials |
| NCT04866108 | A Phase II Study of Fruquintinib Combined With Capecitabine as First-line Treatment for Advanced Metastatic Colorectal Cancer Unsuitable for Intravenous Chemotherapy | unknown | Phase 2 | 49 | Beijing Friendship HospitalOTHER | 1 | Aug 18, 2022 | clinicaltrials |
| NCT05004831 | Fruquintinib Combined With TAS-102 in the Treatment of Patients With Advanced Metastatic CRC | unknown | Phase 2 | 54 | Sun Yat-sen UniversityOTHER | 1 | Aug 18, 2022 | clinicaltrials |
| NCT05016869 | Fruquintinib Plus Capecitabine as Maintenance Treatment of RAS / BRAF Wild-type Metastatic Colorectal Cancer | unknown | Phase 1 / Phase 2 | 48 | Chinese Academy of Medical SciencesOTHER | 1 | Aug 18, 2022 | clinicaltrials |
| NCT04924179 | Tislelizumab Combined With Fruquintinib and SBRT as Athird-line and Posterior Line Treatment in Patients With Advanced CRC | unknown | Phase 2 | 25 | Huazhong University of Science and TechnologyOTHER | 1 | Aug 17, 2022 | clinicaltrials |
| NCT04683965 | Pemetrexed and TAS-102 in Combination With Bevacizumab in Refractory Colorectal Cancer | unknown | Phase 2 | 27 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Aug 2, 2022 | clinicaltrials |
Data updated 23 days agoSource updated May 11, 2023source: clinicaltrials